

Voyageur Pharmaceuticals Ltd. Announces Issuance of Shares to Pay for Deposits and Debt

written by Raj Shah | May 11, 2022

May 10, 2022 ([Source](#)) – Voyageur Pharmaceuticals Ltd. (TSXV:VM) (USA:VYYRF) (the “Company” or “Voyageur”) has agreed to pay deposits for work on design of the Company’s manufacturing facility and pay other existing debts in an amount of up to \$100,000 through the issuance of common shares of the Company (“Common Shares”) at a deemed price per share of \$0.11 based on the closing price of the Common Shares at the close of trading on May 10, 2022 (the “Share Payments”).

The Share Payments are subject to regulatory approval, including the approval of the TSX Venture Exchange. The Common Shares issued pursuant to the Share Payments are subject to a four month hold period from the date of issuance.

About Voyageur

Voyageur is a Canadian public company listed on the TSXV under the trading symbol VM. Voyageur is focused on the development of barite and iodine Active Pharmaceutical Ingredients (“API”) and high-performance cost-effective imaging contrast agents for the medical radiology marketplace. Voyageur’s goal is to initially generate positive cash flow from operations using third party GMP pharmaceutical manufacturers in Canada and internationally. Ultimately, Voyageur has plans to build all the required infrastructure to become 100% self-sufficient with all manufacturing. Voyageur owns a 100% interest in three barium sulphate (barite) projects including the Frances Creek property, suitable in grade for the pharmaceutical barite marketplace,

with interests in a high-grade iodine, lithium & bromine brine project located in Utah, USA.

Voyageur is moving forward with its business plan of becoming the only fully integrated company in the radiology medical field, by controlling all primary input costs under the motto of: "From the Earth to the Bottle".

For Further Media Information or to set up an interview, please contact:

Brent Willis

President & CEO

E brent@vpharma.ca

www.voyageurpharmaceuticals.ca

Ron Love

CFO

T 403.818.6086

E ronl@vpharma.ca

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Cautionary Statement Regarding "Forward-Looking" Information

This news release may contain certain forward-looking information and statements, including without limitation the receipt of regulatory approval for the issuance of the Share Payments. All statements included herein, other than statements of historical fact, are forward-looking information and such information involves various risks and uncertainties. There can be no assurance that such information will prove to be accurate, and actual results and future events could differ materially

from those anticipated in such information. A description of assumptions used to develop such forward-looking information and a description of risk factors that may cause actual results to differ materially from forward-looking information can be found in the Company's disclosure documents on the SEDAR website at www.sedar.com. Voyageur does not undertake to update any forward-looking information except in accordance with applicable securities laws.